MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Surgical Technology _ Cardiovascular, Cardiac & Cardiology Companies
enVVeno Medical Corporation (NASDAQ:NVNO), formerly, Hancock Jaffe Laboratories, Inc. (HJLI)
Organization & Developments: enVVeno Medical
Parents
enVVeno Medical Corporation (NASDAQ:NVNO), formerly, Hancock Jaffe Laboratories, Inc. (HJLI)
Children
*Developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI).
*Lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI including the potential to heal recurring venous leg ulcers.
*The company's VenoValve and enVVe segments look to provide a remedial breakthrough in the common disease segment of chronic venous insufficiency
2021: FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve
2021: Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
2022: enVVeno Medical (NVNO) Investor Presentation - Slideshow_ seekingalpha.com
2022: enVVeno Medical: Unique Exposure To Venous Treatment Domai_seekingalpha.com
2024: enVVeno: The Road To Approval Seems Open From Here On
Hancock Jaffe Laboratories, Inc. (HJLI)
Jumps
Finance & Acquisition: enVVeno Medical
Key People: enVVeno Medical